DN203316, a novel PPARδ agonist, suppresses ferroptotic signaling and fibrogenesis in metabolic dysfunction-associated steatohepatitis - PubMed
5 hours ago
- #MASH fibrosis
- #PPARδ agonist
- #ferroptosis
- DN203316 is a novel PPARδ agonist that suppresses ferroptosis and fibrosis in metabolic dysfunction-associated steatohepatitis (MASH).
- Dietary cholesterol downregulates PPARδ, leading to ferroptosis in hepatocytes and activation of hepatic stellate cells (HSCs) via exosomal DNA and STING-TBK1-IRF3 signaling.
- The study shows that DN203316 reverses these effects, reducing lipid peroxidation, inflammation, and fibrosis without causing metabolic issues, supported by clinical data from MASH patients.